[go: up one dir, main page]

YU79103A - Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora - Google Patents

Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora

Info

Publication number
YU79103A
YU79103A YU79103A YUP79103A YU79103A YU 79103 A YU79103 A YU 79103A YU 79103 A YU79103 A YU 79103A YU P79103 A YUP79103 A YU P79103A YU 79103 A YU79103 A YU 79103A
Authority
YU
Yugoslavia
Prior art keywords
diazepin
benzo
dihydro
derivatives
mglur2 antagonists
Prior art date
Application number
YU79103A
Other languages
English (en)
Inventor
Geo Adam
Erwin Goetschi
Vincent Mutel
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of YU79103A publication Critical patent/YU79103A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj pronalazak se odnosi na derivate dihidro-benzo[b][1,4]-diazepin-2-ona, opšte formule I, naznačene time što R1, R2, R3, X i Y imaju značenje opisano u specifikaciji. Pronalazak se takodje odnosi na medikamente koji sadrže ova jedinjenja, postupak njihovog dobijanja, kao i na njihovu primenu za proizvodnju medikamenata za terapiju ili prevenciju akutnih i/ili hroničnih neuroloških poremećaja.[This invention is concerned with dihydro-benzo[b][1,4]diazepin-2-one derivatives of general formula (I) wherein R1, R2, R3 and Y are as defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.
YU79103A 2001-04-12 2002-04-02 Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora YU79103A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
YU79103A true YU79103A (sh) 2006-05-25

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
YU79103A YU79103A (sh) 2001-04-12 2002-04-02 Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora

Country Status (37)

Country Link
US (1) US6548495B2 (sh)
EP (1) EP1379522B1 (sh)
JP (1) JP4043953B2 (sh)
KR (1) KR100566178B1 (sh)
CN (1) CN1268626C (sh)
AR (1) AR035456A1 (sh)
AT (1) ATE287883T1 (sh)
AU (1) AU2002310912B2 (sh)
BG (1) BG108253A (sh)
BR (1) BR0208887A (sh)
CA (1) CA2441771C (sh)
CZ (1) CZ20033002A3 (sh)
DE (1) DE60202761T2 (sh)
DK (1) DK1379522T3 (sh)
EC (1) ECSP034796A (sh)
ES (1) ES2235044T3 (sh)
GT (1) GT200200072A (sh)
HR (1) HRP20030791B1 (sh)
HU (1) HUP0400991A3 (sh)
IL (2) IL158021A0 (sh)
JO (1) JO2273B1 (sh)
MA (1) MA27011A1 (sh)
MX (1) MXPA03009317A (sh)
MY (1) MY130369A (sh)
NO (1) NO325300B1 (sh)
NZ (1) NZ528345A (sh)
PA (1) PA8543201A1 (sh)
PE (1) PE20021072A1 (sh)
PL (1) PL367086A1 (sh)
PT (1) PT1379522E (sh)
RU (1) RU2270197C2 (sh)
SI (1) SI1379522T1 (sh)
SK (1) SK13692003A3 (sh)
UY (1) UY27259A1 (sh)
WO (1) WO2002083665A1 (sh)
YU (1) YU79103A (sh)
ZA (1) ZA200307242B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU27902A (sh) 1999-10-15 2004-11-25 F. Hoffmann-La Roche Ag. Derivati benzodiazepina
CN1856312A (zh) * 2003-07-25 2006-11-01 弗·哈夫曼-拉罗切有限公司 治疗急性和/或慢性神经系统疾病的mGluR2拮抗剂和AChE抑制剂的组合产品
EP1812392B1 (en) 2004-11-05 2008-07-09 F.Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008128889A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
US8722894B2 (en) * 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
MX2015004604A (es) 2012-10-23 2015-10-08 Hoffmann La Roche Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
TWI622592B (zh) * 2013-02-28 2018-05-01 衛材R&D企管股份有限公司 四氫咪唑並[1,5-d][1,4]氧氮雜卓衍生物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
JP2003506440A (ja) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 中枢神経系に関連する疾患の処置のための1,4−ジアゼピン誘導体
PT1224174E (pt) * 1999-10-15 2004-01-30 Hoffmann La Roche Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
YU27902A (sh) * 1999-10-15 2004-11-25 F. Hoffmann-La Roche Ag. Derivati benzodiazepina

Also Published As

Publication number Publication date
EP1379522A1 (en) 2004-01-14
NO325300B1 (no) 2008-03-25
BG108253A (bg) 2005-03-31
GT200200072A (es) 2003-06-19
EP1379522B1 (en) 2005-01-26
ECSP034796A (es) 2003-12-01
MXPA03009317A (es) 2004-02-12
CA2441771A1 (en) 2002-10-24
KR100566178B1 (ko) 2006-03-29
JP4043953B2 (ja) 2008-02-06
CN1522252A (zh) 2004-08-18
UY27259A1 (es) 2002-10-31
SI1379522T1 (en) 2005-04-30
HUP0400991A2 (hu) 2004-08-30
ATE287883T1 (de) 2005-02-15
NZ528345A (en) 2005-04-29
HRP20030791A2 (en) 2005-06-30
DE60202761D1 (de) 2005-03-03
PL367086A1 (en) 2005-02-21
WO2002083665A1 (en) 2002-10-24
NO20034496L (no) 2003-10-08
CZ20033002A3 (cs) 2004-03-17
DE60202761T2 (de) 2006-01-12
MY130369A (en) 2007-06-29
PT1379522E (pt) 2005-05-31
IL158021A0 (en) 2004-03-28
AU2002310912B2 (en) 2005-06-16
HRP20030791B1 (en) 2006-06-30
AR035456A1 (es) 2004-05-26
ES2235044T3 (es) 2005-07-01
US6548495B2 (en) 2003-04-15
NO20034496D0 (no) 2003-10-08
RU2003130648A (ru) 2005-04-10
JP2004525965A (ja) 2004-08-26
JO2273B1 (en) 2005-04-07
ZA200307242B (en) 2004-12-16
PE20021072A1 (es) 2002-12-07
SK13692003A3 (sk) 2004-05-04
BR0208887A (pt) 2004-06-29
CN1268626C (zh) 2006-08-09
DK1379522T3 (da) 2005-05-30
KR20030088502A (ko) 2003-11-19
IL158021A (en) 2010-04-15
HK1068339A1 (en) 2005-04-29
RU2270197C2 (ru) 2006-02-20
US20020198197A1 (en) 2002-12-26
MA27011A1 (fr) 2004-12-20
HUP0400991A3 (en) 2009-06-29
PA8543201A1 (es) 2002-10-31
CA2441771C (en) 2008-12-30

Similar Documents

Publication Publication Date Title
MY140271A (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii
YU79103A (sh) Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora
MY176608A (en) Dihydrobenzodiazepin-2-one derivatives iii
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
MXPA03000428A (es) Derivados de tetrahidro-heterociclo-acepinil-pirimidina.
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
TW200500344A (en) Novel compounds
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
GB0329214D0 (en) Novel compounds
GEP20104959B (en) Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
BG104983A (en) Aryl fused azapolycyclic compounds
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
MXPA05011163A (es) Derivados de 3-benzhidriliden-8-azabiciclo[3.2.1]octano con actividad de receptores opioides.
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
PT1651592E (pt) Novas dibenzo[b,f]oxepino-10-carboxamidas e suas utilizações farmacêuticas
MXPA06000193A (es) Derivados de imidazol iii.
CA2299036A1 (en) 4-phenyl-4-heteroarylpiperidine derivatives
JO2495B1 (en) Derivatives of dihydropenzene-2-one III
WO2000078751A3 (en) Compounds for use in treatment of neurological disorders